More about
Walk Test
News
December 13, 2019
1 min read
Save
EMPERIAL top-line results: Empagliflozin for HFpEF, HFrEF fails to improve exercise ability

Boehringer Ingelheim and Eli Lilly and Co. announced negative top-line results for its EMPERIAL-Reduced and EMPERIAL-Preserved trials, nothing that the SGLT2 inhibitor empagliflozin did not meet the primary endpoint of improvements in exercise ability according to the 6-minute walk test from baseline to 12 weeks compared with placebo in patients with chronic HF with reduced and preserved ejection fraction.
News
August 23, 2019
2 min read
Save